Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5614038 | 0.98 | LMNA (0.61) | LMNAPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL5909057 | 0.91 | CA12 (0.58) | LMNAPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL11220601 | 0.84 | LMNA (0.85) | LMNAPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL765958 | 0.83 | L3MBTL1 (0.74) | LMNAPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL12065463 | 0.83 | ALDH1A1 (0.68) | LMNAPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL10872851 | 0.83 | LMNA (0.69) | LMNAPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL10604141 | 0.83 | LMNA (0.63) | LMNAPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL8158111 | 0.83 | NR1H4 (0.54) | LMNAPOLBALDH1A1GAAHDAC1 | |
| SCHEMBL9625469 | 0.83 | MPO (0.59) | LMNAL3MBTL1ALDH1A1KMT2AMAPT | |
| SCHEMBL13702393 | 0.83 | PLK1 (0.66) | LMNAALDH1A1HDAC6KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1433296-A | Nail enamel composition containing urea-modified thixotropic agent | OREAL (FR) | 2003-07-30 | — | — | CN | claimed |
| EP-0287421-B1 | PROCESS FOR THE CYCLIC PRODUCTION OF HYDROGEN PEROXIDE | ELF ATOCHEM S.A. (FR) | 1991-06-05 | — | — | EP | claimed |
| US-4803063-A | REDOX REACTION OF QUINONES IN AROMATIC AMIDE SOLVENT | ATOCHEM (FR) | 1989-02-07 | — | — | US | claimed |
| EP-0287421-A1 | Process for the cyclic production of hydrogen peroxide | ELF ATOCHEM S.A. (FR) | 1988-10-19 | — | — | EP | claimed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4227298-A1 | SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF | Technoderma Medicines Inc. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116223598-A | Electrochemical detection method of menthol based on competition with ferrocene for entering beta-cyclodextrin | 东南大学 | 2023-06-06 | — | — | CN | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2023016134-A1 | COMPOUND CONTAINING TETRAHYDROPTERIN STRUCTURE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023011301-A1 | JAK INHIBITOR WITH HIGH ORAL BIOAVAILABILITY | 嘉兴特科罗生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-115677696-A | Preparation method of benzonaphthyridine derivative | 华侨大学 | 2023-02-03 | — | — | CN | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | LMNA 822/4885POLB 917/4885L3MBTL1 2434/4885 |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | LMNA 1356/4885POLB 3905/4885L3MBTL1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.